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Abstract
Staphylococcal biofilms are a major concern in both clinical and food settings because they are an important source of
contamination. The efficacy of established cleaning procedures is often hindered due to the ability of some antimicrobial
compounds to induce biofilm formation, and to the presence of persister cells, a small bacterial subpopulation that exhibits
multidrug tolerance. Phage lytic enzymes have demonstrated antimicrobial activity against planktonic and sessile bacteria.
However, their ability to lyse and/or select persister cells remains largely unexplored so far. In this work, the lytic activity of
the endolysin LysH5 against Staphylococcus aureus and Staphylococcus epidermidis biofilms was confirmed. LysH5 reduced
staphylococcal sessile cell counts by 1–3 log units, compared with the untreated control, and sub-inhibitory concentrations
of this protein did not induce biofilm formation. LysH5-surviving cells were not resistant to the lytic activity of this protein,
suggesting that no persister cells were selected. Moreover, to prove the lytic ability of LysH5 against this subpopulation,
both S. aureus exponential cultures and persister cells obtained after treatment with rifampicin and ciprofloxacin were
subsequently treated with LysH5. The results demonstrated that besides the notable activity of endolysin LysH5 against
staphylococcal biofilms, persister cells were also inhibited, which raises new opportunities as an adjuvant for some
antibiotics.
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Introduction
Two staphylococcal species, Staphylococcus aureus and Staph-
ylococcus epidermidis, are the main cause of hospital-associated
infections [1,2]. S. epidermidis is a common etiological agent of
nosocomial infections, mostly occurring in immune compromised
patients with implanted medical devices [3]. Methicillin-resistant
S. aureus (MRSA) strains are also responsible for both health care
and community-associated infections, mostly involving skin and
wound infections, pneumonia, severe sepsis and endocarditis [4].
In addition, S. aureus is one of the major bacterial agents causing
foodborne diseases in humans due to the production of
enterotoxins [5].
Pathogenicity of both species is clearly associated with their
ability to form biofilms on biotic and abiotic surfaces, providing
high resistance to host defenses and antibiotics, and also to
cleaning and disinfection processes [2]. The ability to form
biofilms allows S. aureus to survive in hostile environments, such
as food industry surfaces [6], and this enhances the recurrence of
food contamination. The ability to form biofilms in both species is
due to the production of an extracellular material that contributes
to intercellular aggregation and attachment to surfaces. In most
cases, this matrix is composed of exopolysaccharides such as poly-
N-acetyl-b-(1,6)-glucosamine (PIA/PNAG), teichoic acids, DNA
and specific proteins [2]. S. aureus strains that are not reliant on
polysaccharides for biofilm formation have also been identified.
Specific proteins such as Bap [7], Spa [8], FnBPA, FnBPB [9], and
SasG [10], are surface adhesins involved in biofilm development.
In S. epidermidis an extracellular matrix-binding protein (Embp) is
necessary and sufficient to promote protein-dependent biofilm
formation [11]. In addition, the accumulation-associated protein
(Aap) also mediates intercellular and surface adhesion and is
considered the most important factor contributing to protein-
dependent biofilm formation in S. epidermidis [12].
Bacteria embedded in biofilms are considerably less susceptible
to antibiotics than their planktonic counterparts, mainly due to the
limited access which the antibiotic has into the biofilm [13].
Moreover, several studies have shown that S. aureus biofilm
formation can be stimulated by sub-inhibitory concentrations (sub-
MICs) of some antibiotics [14]. Some bacteria within the biofilm
also show a reduced susceptibility to antibiotics due to their
dormant phenotype. These bacteria, named persister cells, are
genetically identical to susceptible bacteria and give rise to a new
sensitive population after the removal of antibiotic pressure [15].
Persistance is a main cause of concern as it has been observed in
most bacterial species, in relation to different classes of antibiotics,
with persister cells being involved in recurrent infections [16]. In
this regard, several strategies for the clearance of staphylococcal
biofilms, other than disinfectants and antibiotics, have been
assayed. These include PIA-degrading enzymes like dispersin B
[17], the peptidoglycan-degrading enzyme lysostaphin [18],
bacteriocins [19] and bacteriophages [20–23].
Recently, phage lytic proteins (endolysins and virion-associated
peptidoglycan hydrolases) have shown a potent antimicrobial
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activity against planktonic bacteria [24,25]. They have been
investigated as therapeutic agents and biopreservatives against a
range of pathogens, such as Bacillus anthracis, Streptococcus
pneumoniae, S. aureus, and Streptococcus suis. Moreover, S.
aureus, S. suis, S. pneumonia and Streptococcus pyogenes biofilms
have been successfully removed by endolysins [26–29]. We have
previously identified and characterized the endolysin LysH5
encoded by the S. aureus phage vB_SauS-phiIPLA88, which
showed a high degree of similarity (97%) with the endolysin from
phage phi11, for which anti-biofilm activity has previously been
reported [30]. LysH5 has two catalytic domains (CHAP domain
and amidase-2 domain) and a cell wall binding domain (SH3b).
This protein is able to lyse a wide range of staphylococci, including
bovine and human S. aureus and S. epidermidis [31]. A synergistic
antimicrobial activity was previously observed with both the
bacteriocin nisin [32] and the virion-associated peptidoglycan
hydrolase HydH5 and its derivative fusion proteins [33].
The aim of this study was to determine the efficacy of the
endolysin LysH5 to remove the biofilms formed by S. aureus and
S. epidermidis strains. We have studied the ability of LysH5 to
induce biofilms, to select persister cells, and finally, to see if LysH5
was also able to kill persister cells previously selected by antibiotics.
Material and Methods
Bacterial strains, growth media and proteins
Staphylococcal strains (Table 1) were routinely cultured in TSB
broth (Tryptic Soy Broth, Scharlau, Barcelona, Spain) at 37uC
with shaking, or in TSB plates containing 2% (w/v) bacteriological
agar (TSA).
LysH5 purification was performed as previously described [32].
The LysH5 specific activity against the different strains was
calculated as the DOD per mg of protein per min [31].
Lysostaphin was obtained from Sigma (Sigma, Missouri, USA).
Biofilm assays
For biofilm formation the protocol of Herrera et al., (2007), was
used with some modifications [34]. Briefly, overnight (o/n)
staphylococcal cultures were diluted in fresh TSBg (TSB
supplemented with 0.25% w/v D-(+)-glucose) up to 106CFU/ml,
and 200 ml were poured into TC Microwell 96U w/lid nunclon D
SI plates (Thermo Scientific, NUNC, Madrid, Spain), and
incubated at 37uC for 24 h. Wells were washed twice with sterile
phosphate-buffered saline (PBS buffer) (137 mM NaCl, 2.7 mM
KCl, 10 mM Na2HPO4 and 2 mM KH2PO4; pH 7.4).
To determine the counts of bacteria attached to each well once
the biofilm was developed, the well was scratched twice with a
sterile swab and then immersed into 9 ml of PBS buffer. A
vigorous shaking for 1 min allowed the disaggregation of the
biofilm [34]. Finally, several decimal dilutions were plated onto
TSA and incubated at 37uC.
Likewise, the biofilm that had adhered to the surfaces of the
wells was observed by staining with crystal violet (0.1% w/v) for
15 min, followed by a gentle wash with water and de-staining in
acetic acid (33% v/v). Absorbance was measured at a wavelength
of 595 nm [9]. All the assays were performed using two biological
replicates.
Treatment of staphylococcal biofilms with LysH5
24 h-old biofilms were developed as described previously. After
the washing step with PBS buffer, 0.15 mM of LysH5, 0.2 mM of
lysostaphin, or 200 ml of sodium phosphate buffer (50 mM pH 7)
for control purposes, were added to each well. Plates were
incubated for 6 h at 37uC and cell counts were measured as
described above. Surviving cells were recovered after treatment by
scratching the well with a sterile swab and transferred to 2 ml of
TSB medium. For two-step treatment assay, 24 h-old biofilms
were first treated with LysH5 (0.15 mM) for 6 h, then washed and
treated again with LysH5 (0.15 mM) for 12 h. Cell counts were
measured as described above.
Determination of minimal inhibitory concentration (MIC)
of LysH5 and biofilm induction
The MIC of LysH5 was determined in duplicate by a
conventional broth microdilution technique in TSB. Two-fold
dilution of LysH5 (0.4 mM) was made in microtiter plates and each
well was inoculated with 106 CFU. The MIC was defined as the
lowest protein concentration that inhibited visible bacterial growth
after 24 h of incubation at 37uC.
The ability of LysH5 to induce the formation of biofilms was
tested using sub-inhibitory concentrations of the protein, ranging
from 0 to 6 mg/ml (0–0.1 mM) for S. aureus 15981, S. aureus 132,
S. aureus IPLA1, S. aureus IPLA6 and S. epidermidis YLIC17;
Table 1. Strains used in this work, origin and relevant properties.
Strain Origin Relevantproperties Reference
S. aureus 15981 Clinical isolate Produces PNAG [42]
ISP479r Clinical isolate
V329 Bovine subclinical mastitis Expressesbapprotein [7]
132 Clinical isolate Produces PNAG [43]
IPLA1 Dairy industry surface Genes icaA and icaD [6]
IPLA16 Meat industry surface
SA113 - NCTC8325 derivative, agr–, 11-bp deletion in rsbU [44]
Newman - Sub-inhibitory concentrations of meticillin induces
biofilm formation.
[45]
S. epidermidis B Breast milk of women suffering
infectious mastitis
Genes icaA and icaD [46]
YLIC17
DG2n
doi:10.1371/journal.pone.0107307.t001
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and from 0 to 3 mg/ml (0–0.05 mM) for S. aureus ISP479r, S.
aureus V329, S. epidermidis B and S. epidermidis DG2n. S. aureus
Newman treated with 0–10 mg/ml of methicillin was used as a
positive control of biofilm formation under sub-inhibitory
concentrations of this antibiotic [14]. The biofilm induction value
for each strain (expressed as relative absorbance) was defined as
the absorbance value measured after crystal violet staining at each
concentration of LysH5, or methicillin, divided by the absorbance
value in the absence of the antimicrobials. For CFU determination
of non-adhered cells, planktonic cells of each well were diluted and
plated onto TSA plates. All experiments were conducted using two
biological replicates.
Biochemical characterization of the biofilm matrix
24 h-old staphylococcal biofilms were washed with PBS and
then treated for 1 h 37uC either with a solution of 10 mM sodium
metaperiodate in 50 mM sodium acetate buffer (pH 4.5) (sodium
metaperiodate treatment is used to disrupt the extracellular
polysaccharides), with 100 mg/ml of proteinase K (Sigma, Madrid,
Spain) in 20 mM Tris (pH 7.5) and 100 mM NaCl, or with
100 mg/ml of DNAseI (Sigma, Madrid, Spain) in 150 mM of
NaCl and 1 mM CaCl2. After treatments, the biofilms were
washed with water, stained with crystal violet, and the absorbance
measured as described above.
LysH5 activity against persister cells
To determine if treatment of planktonic cells with LysH5
yielded a subpopulation of persister cells, overnight cultures of S.
aureus 15981 were used to inoculate TSB fresh medium and
grown at 37uC up to OD600 = 0.5. Then, LysH5 was added at 1 to
5-fold MIC (0.1–0.5 mM, respectively) and cultures were incubat-
ed at 37uC for 3 h.
Lytic activity of LysH5 against previously selected persister cells
was also tested as follows. Persister cells of S. aureus SA113 were
selected as described previously [35] after the treatment of
exponential cultures (OD600 = 0.5) with 2 mg/ml of rifampin or
3 mg/ml of ciprofloxacin (100 and 10-fold MIC, respectively) for
4 h. LysH5 was then added at 0.5 mM and incubated at 37uC for 4
additional hours.
For CFU determinations, samples were taken before and during
the antimicrobial challenge and appropriate dilutions plated onto
TSA plates. All experiments were conducted using two biological
replicates.
Low-temperature scanning electron microscopy (LTSEM)
LTSEM was used to visualize the structure of the 24 h-old
biofilms before and after treatment with the endolysin LysH5. The
biofilms were grown on a glass cover lid and visualized at 2135uC
with a DSM 960 Zeiss scanning electron microscope as previously
described [36].
Statistical analysis
Statistical analysis was performed in order to establish any
significant differences between the total bacteria number in the
control and treated biofilms, and between the control and treated
planktonic cultures. The differences were expressed as the mean6
standard error and were determined by one-way analysis of
variance (ANOVA) and the LSD test was used for a comparison of
means at a level of significance P,0.05.
Results
LysH5 is effective against staphylococcal biofilms
The ability of LysH5 to remove staphylococcal biofilms and kill
sessile cells was determined on six S. aureus and three S.
epidermidis strains. Three S. aureus clinical strains producing a
polysaccharide matrix and one protein-dependent biofilm strain
from bovine origin were tested. Additionally, two S. aureus strains
isolated from a food environment and three S. epidermidis of
clinical origin, all of them carrying biofilm related genes, were
included in the assay (Table 1). 24 h-old biofilms developed on 96-
well polystyrene plates were treated with LysH5 (0.15 mM) and
lysostaphin (0.2 mM) and biofilm removal was determined after
6 h of incubation. LysH5 showed a notable disrupting activity
against biofilms of both S. aureus and S. epidermidis strains, as
judged by the reduction of the attached bacterial counts by 1–3 log
units per well (Fig. 1). The activity of this protein turned out to be
higher than that of lysostaphin, with the exception of the biofilms
developed by S. aureus 15981 and S. aureus ISP479r, against
which lysostaphin was more effective. As expected, lysostaphin was
quite ineffective against S. epidermidis biofilms, while LysH5
showed similar viable count reduction percentages against strains
of both species.
The variability observed in the activity of LysH5 against the
different biofilms might be determined by the susceptibility of the
planktonic cells to LysH5 but also by the composition of the
extracellular material which might impair or limit the access of
LysH5 to the bacterial cells. However, we could not establish a
correlation between the activity of LysH5 against each biofilm and
the intrinsic susceptibility of each strain or the composition of the
biofilm matrix. As shown in Table 2, the specific activity of LysH5
on exponentially growing S. epidermidis cells was rather low (1.5–
3.8 DOD/mg min) in contrast to that shown by S. aureus cells
(2.1–16.5 DOD/mg min). However, LysH5 removed staphylo-
coccal biofilms regardless of the chemical composition of the
extracellular matrix (polysaccharidic, protein or DNA based
biofilms) (Table 3). Moreover, attached viable cells were recovered
from the wells after a single exposure to LysH5 and the biofilm
formation ability of these isolates was determined by crystal violet
staining. Absorbance values identical to those of untreated strains
were observed (Table S1). Thus, the surviving cells do not seem to
have an increased biofilm-forming ability. Of note, a second
LysH5 treatment resulted in the decrease of the staphylococcal
populations to undetectable levels (,10 CFU/well) (Fig. 1). This
suggests that the viable cells remaining attached to the well surface
after the first LysH5 treatment were not persister cells as they
remained susceptible to the endolysin.
LTSEM supports biofilm disruption by LysH5
Electron micrographs reinforced our results as they showed
unstructured biofilms as a consequence of the treatment with
LysH5 (Fig. 2). In the case of S. aureus 15981, a polysaccharide-
dependent biofilm producer, cells were arranged in layers and
covered by a thin matrix that kept them attached to surface
(Fig. 2A); after LysH5 treatment, no cells or extracellular material
were observed (Fig. 2B). S. epidermidis YLIC17 biofilm structure
showed cell aggregates producing a compact biofilm covered by a
polysaccharidic layer (Fig. 2C) which was not removed by the
endolysin treatment but whole cells were no longer present
(Fig. 2D). This observation suggests that LysH5 was able to
penetrate through the matrix structure.
Staphylococcal Biofilm Removal
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Sub-inhibitory concentrations of LysH5 do not induce
staphylococcal biofilm and prevent its formation in some
strains
To evaluate a putative inducing effect of LysH5 on biofilm
formation, S. aureus strains were grown in the presence of LysH5
at concentrations lower than the MIC (Table 2) and checked for
biofilm formation. As a control for antibiotic-induced biofilm, the
strain S. aureus Newman was used [14]. As expected, a relative
absorbance increase of 18-fold was observed for this strain treated
with sub-inhibitory concentrations of methicillin and further
stained with crystal violet. Significantly, induction in biofilm
formation was also observed for strains S. aureus 132 and S.
aureus IPLA1 (1.6 and 1.3 times, respectively) (Fig. S1). In the
presence of sub-MIC concentrations of LysH5, bacterial growth
was not inhibited and biofilm induction was not observed in any of
the tested strains (Fig. S2). Interestingly, the staphylococcal strains
behaved differently in the presence of sub-inhibitory LysH5
concentrations (Fig. 3). In fact, biofilm formation by S. aureus
15981, S. aureus 132 and S. epidermidis B was completely
inhibited (Fig. 3A), while biofilm growth of S. aureus ISP479r, S.
aureus V329, S. aureus IPLA1 and S. epidermidis YLIC17 was
reduced, but not completely inhibited when growing at 0.256 to
0.56MIC of LysH5 (Fig. 3B). For the remaining strains, S. aureus
IPLA16, S. aureus Newman and S. epidermidis DG2n, no
inhibition of biofilm formation was observed under sub-inhibitory
concentrations (Fig. 3C).
LysH5 is active against S. aureus planktonic persister cells
To assess if the treatment of staphylococcal planktonic cultures
with LysH5 could select persister cells, S. aureus 15981
exponential cultures were treated with increasing LysH5 concen-
trations. Bacterial counts decreased as LysH5 concentration
increased, and no surviving bacteria were detected at 0.5 mM
endolysin (Fig. 4A). Similar results were obtained when S. aureus
SA113 was treated with increasing concentrations of LysH5 (data
not shown). To further confirm the effectiveness of LysH5,
Figure 1. Removal of 24 h-old biofilms of S. aureus and S. epidermidis. Biofilms of S. aureus 15981, ISP479r, V329, 132, IPLA1 and IPLA16 and S.
epidermidis B, YLIC17and DG2n were treated with 0.15 mM of LysH5 (light grey) and 0.2 mM of lysostaphin (white) during 6 hours. Alternatively,
biofilms were treated with 0.15 mM of LysH5 during 6 hours, followed by another treatment with the endolysin for 12 hours (gross line in X axis).
Control biofilms are represented in black. Adhered cell counts were expressed as log CFU/well. Bacteria detection threshold (,10 CFU/ml). Means
and standard deviations were calculated from two biological replicates. Bars having an asterisk are significantly different from the control (ANOVA;
P,0.05) and bars with a lower case ‘a’ indicates a significantly difference between the lysostaphin treatment and the treatment with LysH5 (ANOVA;
P,0.05).
doi:10.1371/journal.pone.0107307.g001
Table 2. Sensitivity of staphylococcal strains to LysH5.
Strain Specific activity (DOD/mg min) MIC (mM)
S. aureus 15981 13.460.8 0.1
ISP479r 16.560.3 0.05
V329 8.760.1 0.05
132 14.360.4 0.1
IPLA1 2.160.6 0.1
IPLA16 3.060.1 0.05
Newman 11.660.3 0.1
SA113 12.160.2 0.1
S. epidermidis B 3.860.1 0.05
YLIC17 1.960.2 0.1
DG2n 1.560.3 0.05
Specific activity of LysH5 against staphylococcal exponential cultures (DOD per mg of protein per min) and MIC values of LysH5 determined in staphylococcal broth
cultures. The values are means 6 standard deviations two biological experiments.
doi:10.1371/journal.pone.0107307.t002
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planktonic persister cells were isolated from S. aureus SA113 by
treatment with either rifampicin or ciprofloxacin [35]. Fig. 4B
shows the selection of persister cells by rifampicin and ciproflox-
acin with the typical biphasic killing curve, and their further
behavior after the addition of 0.5 mM LysH5. Indeed, no viable
bacteria were detected after 2 h of incubation at 37uC, supporting
the LysH5 lytic potential against this subpopulation of bacteria
that can survive the antibiotic challenge.
Discussion
The endolysin LysH5 has a remarkable activity to lyse S. aureus
and S. epidermidis planktonic cells [31], which has been extended
against staphylococcal biofilms in the current work. Low
concentrations of LysH5 (0.15 mM) were effective to decrease
viable bacteria inside biofilms formed by either S. aureus or S.
epidermidis strains. No correlation was observed between the
Table 3. Ability of specific treatments to remove biofilm formed by staphylococcal strains.
Strain Removed biofilm
NaIO4 Proteinase K DNAse I
S. aureus 15981 +++ 2 2
ISP479r ++ ++ +
V329 2 +++ ++
132 + + +
IPLA1 ++ + 2
IPLA16 ++ ++ 2
S. epidermidis B +++ 2 2
YLIC17 +++ 2 +
DG2n +++ 2 +
Extracellular components of the biofilm matrix were estimated from the percentage of removed biofilm with specific treatments; sodium metaperiodate (NaIO4),
proteinase K and DNAseI (+= 30%; ++= 30–70% and +++.70%).
doi:10.1371/journal.pone.0107307.t003
Figure 2. LTSEM micrographs of 24 h-old biofilms formed by S. aureus and S. epidermidis. Not treated biofilms of S. aureus 15981 and S.
epidermidis YLIC17 are represented in A and C, respectively; biofilms after treatment with LysH5 are represented in B and D.
doi:10.1371/journal.pone.0107307.g002
Staphylococcal Biofilm Removal
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ability of LysH5 to remove biofilms and the origin of the strains
(clinical, food), the extracellular matrix (polysaccharide, protein/
DNA) or the peptidoglycan composition, although the latter could
have an impact on LysH5 activity, as shown by the higher specific
activity of LysH5 against S. aureus versus S. epidermidis
planktonic cells [31] (Table 2). However, low diffusion of LysH5
inside biofilms might represent the main limitation to protein
activity, as judged by the similar activity of LysH5 against S.
aureus and S. epidermidis biofilms (Fig. 1).
Beyond the ability of endolysins to remove biofilms, the aim of
this work was to study the effects of LysH5 on both biofilm
formation and putative surviving cells after the LysH5 treatment.
In this regard, we have determined the impact of the expected low
diffusion of LysH5 through the extracellular material and the
consequent sub-inhibitory concentration inside the biofilms. Our
results showed no increase in biofilm formation at low concentra-
tions of LysH5, neither in S. aureus nor in S. epidermidis strains.
On the contrary, sub-inhibitory concentrations of many antibiotics
have been reported to enhance the production of PIA in S.
epidermidis biofilms [37] or extracellular DNA in S. aureus
biofilms [14]. It is not totally clear which mechanism mediates
biofilm induction by some antibiotics but it is thought to be a
Figure 3. Behavior of 24 h-old biofilms formed by S. aureus and S. epidermidis strains, grown in the presence of sub-inhibitory
concentrations of LysH5. Three strains were selected as representative of biofilm behavior (A) Prevention of the biofilm formation (S. aureus
15981); (B) Biofilm reduction (S. aureus ISP479r) and (C) no effect in biofilm formation (S. aureus IPLA16). Biofilm formation was expressed as relative
absorbance (595 nm) of crystal violet stained cultures (treated/untreated cultures)(N). LysH5 concentration is expressed in mM. Each value is the mean
6 standard deviation of two biological replicates.
doi:10.1371/journal.pone.0107307.g003
Figure 4. S. aureus persister cells selection and elimination by LysH5. (A) Activity of different concentrations of LysH5 against exponential
cultures of S. aureus 15981. Means and standard deviations were calculated from two independent assays. Bacteria detection threshold (,10 CFU/ml).
(B) Exponential cultures of S. aureus 113 treated with 2 mg/ml of rifampicin (N), and 3 mg/ml of ciprofloxacin (m) for 4 h to select persister cells and
subsequent treatment with 0.5 mM LysH5 (# and D, respectively). Bacteria detection threshold (,10 CFU/ml). Each value represents the mean 6
standard deviation of two biological replicates.
doi:10.1371/journal.pone.0107307.g004
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consequence of a global stress response [37]. Furthermore, we
found that endolysin LysH5 was able to inhibit biofilm formation
in some strains, even at 0.1256 MIC. A similar effect was
previously described in gallidermin, which represses transcription
of genes involved in primary adhesion and exopolysaccharide
production [19].
One of the main issues in biofilm control is the presence of
persister cells, a small subpopulation of cells that spontaneously
enter a dormant state and, consequently, survive bactericidal
antibiotic treatment. Persisters have been found for almost every
type of antibiotic tested so far [16]. They can reestablish the
population once the stress is removed [38], and are behind
recalcitrant chronic infections [39]. With this in mind, it is
remarkable that no persister bacteria were detected in staphylo-
coccal biofilms after LysH5-treatment. Surviving bacteria were still
sensitive to the endolysin, confirming previous results of the lack of
resistance after the exposure of S. aureus to LysH5 [33]. These
results are also in accordance with the absence of reports on
bacteria resistant to phage endolysins, despite several attempts to
select them [40].
Keeping in mind that approximately 0.001–0.1% of cells of an
isogenic bacterial population display tolerance to antibiotics [14],
we also approached the selection of persister cells from exponential
cultures. In a typical assay for selection of persister cells by
antibiotics, the number of cells in the population is initially
decreased by the antibiotic action, but in a second phase, despite
increasing the time or the antibiotic concentration, a subpopula-
tion of persister cells remain (biphasic curve) [41]. In a similar
assay carried out with LysH5, a lack of persister bacteria after
treatment of S. aureus exponential cultures with LysH5 was
confirmed. The survival rates of bacteria treated with increasing
concentrations of LysH5 failed to show a biphasic curve and no
surviving bacteria were detected at high LysH5 concentration. In
this regard, the fact that LysH5 is able to eliminate persister
bacteria previously selected by two antibiotics, rifampicin and
ciprofloxacin, is particularly interesting. As previously reported
[35], treatment of S. aureus SA113 exponential cultures with
106MIC ciprofloxacin and 1006MIC rifampicin resulted in a
drug-tolerant population of about 103 CFU/ml, which were
further eliminated by LysH5. Our findings suggest that the
endolysin target is accessible in a dormant state in contrast to
antibiotics that need an active target only available in growing
cells. Therefore, delivering endolysin LysH5 as adjuvant to some
antibiotics would be beneficial in the treatment of chronic
bacterial infections. Regarding the disinfection process of indus-
trial food facilities, a two-step treatment could guarantee the
removal of any persistent contamination and open the way to the
use of LysH5 as part of the routine process exploiting putative
synergistic action with other disinfectants/antimicrobials. Despite
these promising results, the total duration of the two-step
treatment (18 h) should be shortened, increasing the concentration
of endolysin in order to achieve the desire efficacy, avoiding the
interruption of the production in food industries. Moreover, our
data should be confirmed in dynamic biofilm models, we provide
additional proof of concept supporting the role of phage
endolysins, not only as antibacterial agents against staphylococcal
biofilms, but also as anti-persister agents, and therefore being an
effective weapon to combat bacterial infections.
Supporting Information
Figure S1 Biofilms formed by S. aureus and S. epider-
midis strains grown in the presence of sub-inhibitory
concentrations of meticillin. (A) Strains with antibiotic-
induction of the biofilm; (B) strains with no effect in biofilm
formation. Biofilm formation was expressed as relative absorbance
(595 nm) of crystal violet stained cultures (treated/untreated
cultures) (N). Each value is the mean 6 standard deviation of two
biological replicates.
(TIF)
Figure S2 Biofilms formed by S. aureus and S. epider-
midis strains grown in the presence of sub-inhibitory
concentrations of LysH5. (A) Strains showing prevention of
the biofilm formation; (B) strains showing a biofilm reduction and
(C) strains with no effect in biofilm formation. Biofilm formation
was expressed as relative absorbance (595 nm) of crystal violet
stained cultures (treated/untreated cultures) (N). Each value is the
mean 6 standard deviation of two biological replicates.
(TIF)
Table S1 Biofilm formation ability of the S. aureus and
S. epidermidis strains. Comparison of 24 h biofilm growth
using o/n cultures of the staphylococcal strains and o/n cultures of
surviving cells recovered after biofilms LysH5 treatment. Values
expressed as absorbance units (595 nm) of crystal violet stained
cultures are the means 6 standard deviations of two independent
experiments.
(DOC)
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